US2015283203A1PendingUtilityA1

Method for treating prostatitis utilizing pore-forming protein proaerolysin

48
Assignee: SOPHIRIS BIO CORPPriority: Dec 15, 2008Filed: Nov 10, 2014Published: Oct 8, 2015
Est. expiryDec 15, 2028(~2.4 yrs left)· nominal 20-yr term from priority
Inventors:J. Curtis Nickel
A61P 29/00C07K 14/195A61K 38/00A61K 38/164C07K 2319/33C07K 16/28A61K 47/6869C07K 2319/30A61K 45/06A61P 13/08A61K 47/6425A61K 47/60
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method of treating prostatitis in a subject, comprising administering to said subject a therapeutically effective amount of PRX302,
 wherein the PRX302 comprises:   an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:3 and which maintains the ability to selectively target and kill normal prostate cells, and an affinity tag.

Join the waitlist — get patent alerts

Track US2015283203A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.